578 related articles for article (PubMed ID: 23610452)
1. Review of guidelines on primary prevention of cardiovascular disease with aspirin: how much evidence is needed to turn a tanker?
Matthys F; De Backer T; De Backer G; Stichele RV
Eur J Prev Cardiol; 2014 Mar; 21(3):354-65. PubMed ID: 23610452
[TBL] [Abstract][Full Text] [Related]
2. Application of U.S. guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan.
Morimoto T; Fukui T; Lee TH; Matsui K
Am J Med; 2004 Oct; 117(7):459-68. PubMed ID: 15464702
[TBL] [Abstract][Full Text] [Related]
3. Aspirin therapy in primary cardiovascular disease prevention: a position paper of the European Society of Cardiology working group on thrombosis.
Halvorsen S; Andreotti F; ten Berg JM; Cattaneo M; Coccheri S; Marchioli R; Morais J; Verheugt FW; De Caterina R
J Am Coll Cardiol; 2014 Jul; 64(3):319-27. PubMed ID: 25034070
[TBL] [Abstract][Full Text] [Related]
4. Aspirin for primary prevention of cardiovascular disease events.
Nemerovski CW; Salinitri FD; Morbitzer KA; Moser LR
Pharmacotherapy; 2012 Nov; 32(11):1020-35. PubMed ID: 23019080
[TBL] [Abstract][Full Text] [Related]
5. Aspirin and the Primary Prevention of Cardiovascular Diseases: An Approach Based on Individualized, Integrated Estimation of Risk.
Volpe M; Battistoni A; Gallo G; Coluccia R; De Caterina R
High Blood Press Cardiovasc Prev; 2017 Sep; 24(3):331-339. PubMed ID: 28573479
[TBL] [Abstract][Full Text] [Related]
6. [Italian intersocietary consensus document on aspirin therapy in primary cardiovascular prevention].
Volpe M; Abrignani MG; Borghi C; Coccheri S; Gresele P; Patti G; Trimarco B; De Caterina R
G Ital Cardiol (Rome); 2014; 15(7-8):442-51. PubMed ID: 25174598
[TBL] [Abstract][Full Text] [Related]
7. Assessing the risk/benefit profile before recommending aspirin for the primary prevention of cardiovascular events.
Rodondi N; Bauer DC
Am J Med; 2004 Oct; 117(7):528-30. PubMed ID: 15464713
[No Abstract] [Full Text] [Related]
8. Are the current recommendations for the use of aspirin in primary prevention of cardiovascular disease applicable in low-income countries?
Noubiap JJ; Nansseu JR
Vasc Health Risk Manag; 2015; 11():503-6. PubMed ID: 26345154
[TBL] [Abstract][Full Text] [Related]
9. What have we learned about using aspirin for primary prevention from the ASCEND and ARRIVE trials?
Tousoulis D
Cardiovasc Res; 2019 Feb; 115(2):e15-e16. PubMed ID: 30668678
[No Abstract] [Full Text] [Related]
10. Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis.
Butalia S; Leung AA; Ghali WA; Rabi DM
Cardiovasc Diabetol; 2011 Apr; 10():25. PubMed ID: 21453547
[TBL] [Abstract][Full Text] [Related]
11. AAA- a further step towards a moratorium for aspirin in the primary prevention.
Minar E
Vasa; 2010 May; 39(2):119-122. PubMed ID: 20521434
[No Abstract] [Full Text] [Related]
12. Aspirin for the primary prevention of cardiovascular events: recommendations and rationale.
U.S. Preventive Services Task Force
Am J Nurs; 2002 Mar; 102(3):67, 69-70. PubMed ID: 11976531
[No Abstract] [Full Text] [Related]
13. Aspirin for primary prevention: yes or no?
Selak V; Elley CR; Wells S; Rodgers A; Sharpe N
J Prim Health Care; 2010 Jun; 2(2):92-9. PubMed ID: 20690297
[TBL] [Abstract][Full Text] [Related]
14. Translating guidelines to practice: findings from a multidisciplinary preventive cardiology programme in the west of Ireland.
Gibson I; Flaherty G; Cormican S; Jones J; Kerins C; Walsh AM; Costello C; Windle J; Connolly S; Crowley J
Eur J Prev Cardiol; 2014 Mar; 21(3):366-76. PubMed ID: 23884981
[TBL] [Abstract][Full Text] [Related]
15. Aspirin for primary cardiovascular disease prevention: time to re-evaluate guidelines?
Barmanray R; Hamblin PS
Intern Med J; 2019 Jan; 49(1):133-134. PubMed ID: 30680892
[No Abstract] [Full Text] [Related]
16. The cardiovascular polypill in high-risk patients.
Lafeber M; Spiering W; Singh K; Guggilla RK; Patil V; Webster R;
Eur J Prev Cardiol; 2012 Dec; 19(6):1234-42. PubMed ID: 22019908
[TBL] [Abstract][Full Text] [Related]
17. Aspirin in primary prevention: USPSTF recommendations.
Aalbers J
Cardiovasc J Afr; 2010; 21(3):176. PubMed ID: 20532445
[No Abstract] [Full Text] [Related]
18. [Aspirin in primary prevention of cardiovascular diseases: how to balance risks and benefits].
De Caterina R; Orlando D; Berti V; Coccheri S
G Ital Cardiol (Rome); 2012; 13(7-8):494-502. PubMed ID: 22781376
[TBL] [Abstract][Full Text] [Related]
19. The New 2019 AHA/ACC Guideline on the Primary Prevention of Cardiovascular Disease.
Bittner V
Circulation; 2020 Dec; 142(25):2402-2404. PubMed ID: 30879338
[No Abstract] [Full Text] [Related]
20. A national survey on aspirin patterns of use and persistence in community outpatients in Italy.
Filippi A; Bianchi C; Parazzini F; Cricelli C; Sessa E; Mazzaglia G
Eur J Cardiovasc Prev Rehabil; 2011 Oct; 18(5):695-703. PubMed ID: 21450601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
